This literature case, reported by a physician, concerns a 63 year old female patient (ethnicity not reported). 
Medical history: negative for end organ dysfunction, brain metastasis, evidence of meningeal metastasis, porphyria, 
glucose-6-phosphate dehydrogenase deficiency or human immunodeficiency virus (HIV) seropositivity. 
Concomitant Medications: motexafin gadolinium, folic acid greater than or equal to 400 microgram daily starting 
seven days before first study treatment and continuing through twenty one days after last study treatment, 
cyanocobalamin one mg within seven days before first study treatment and on day one of cycles four and eight, 
dexamethasone 4 mg twice daily before, day of and day after each study treatment. The patient received second 
line pemetrexed 500 mg/m2 intravenously every three weeks with motexafin gadolinium 15 mg/kg once during the 
first week of each treatment, for the treatment of stage Illb/IV non small cell lung cancer (start date not reported). 
After nine courses of treatment she experienced neutropenic sepsis (grade 5 toxicity) and pneumonia (grade 5 
infection) and ultimately died of cardiogenic shock. Treatment and diagnostics were not reported. It was not 
Print TiMe: 02-SEP-2014 01:09 PM If a field is blank, there is no data for that field Page 620 of 831 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
reported if an autopsy was completed. The physician stated the events of neutropenic sepsis and pneumonia 
were related to pemetrexed but did not offer an opinion for remaining event. Literature Citation: Edelman Martin J. 
MD *, Otterson Gregory MD +, Leach Joseph MD ++, Malpass Thomas MD [S], Salgia Ravi MD [II], Jones Dennie 
MD [P], Mody Tarak D. MD #, Govindan Ramaswamy MD "*. Multicenter Phase II Trial of Motexafin Gadolinium 
and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer. Journal of Thoracic 
Oncology. 2011; 6(3) 1-4.